ALISO VIEJO, Calif., Oct. 22, 2007 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that it has launched EnCor(r), its flagship vacuum-assisted breast biopsy product, and its line of breast biopsy tissue markers in ten countries outside the United States. SenoRx is partnering with local distributors who have breast imaging and/or interventional radiology franchises in Austria, Belgium, England, Hong Kong, Ireland, Luxembourg, The Netherlands, Singapore, Switzerland and Taiwan. EnCor and SenoRx breast tissue markers have previously received the necessary regulatory clearances in the European Economic Community and in these and several other countries in Asia.
"We successfully test marketed EnCor in several countries outside the United States during the first half of 2007," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "Based on those test market results, we concluded that EnCor could be a valuable commercial opportunity outside the United States and began establishing agreements with selected distributors to begin selling EnCor and our line of tissue markers. We intend to further expand marketing of our products in additional countries beginning in 2008.
"In addition, we recently announced the receipt of 510(k) clearance from the FDA for our SenoSonix system, an integration of the EnCor breast biopsy system with state-of-the-art ultrasound imaging from Ultrasonix Medical. We believe that this product is well-suited for markets outside the United States, where practitioners currently perform a large percentage of their breast biopsies with ultrasound imaging. We believe that ultrasound is potentially the fastest-growing of our market segments on a worldwide basis, as well as in the United States," continued Malchow.
About SenoRx
SenoRx (Nasdaq:SENO), which completed its initial public offering of common stock in March 2007, develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis of breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. With 18 products having received FDA 510(k) clearance across the continuum of breast care, SenoRx is developing additional minimally invasive products for diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning SenoRx's ability to successfully market EnCor and other products internationally, the expected growth of such market segment, the expected value of this product to the users in this market, the expected attractiveness to physicians, and future expansion to additional markets are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its prospectus dated March 29, 2007 and its most recent quarterly report on Form 10-Q, in each case as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.